Travere Therapeutics Inc. (TVTX) is now just one step away from potential FDA approval of FILSPARI for expanded use in treating focal segmental glomerulosclerosis (FSGS), following notification that an advisory committee review will no longer be required. Shares are up over 16% at $25 in premarket hours today.
Focal Segmental Glomerulosclerosis or FSGS is a leading cause of kidney failure and currently has no approved pharmacological treatments.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.